Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
148 studies found for:    "Abdominal Neoplasms"
Show Display Options
Rank Status Study
1 Completed Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
Conditions: Abdominal Neoplasms;   Pelvic Neoplasms
Intervention: Drug: Optison
2 Recruiting Nutritional Supplementation in Patients With no Signs of Malnutrition
Conditions: Primary Neoplasm;   Secondary Neoplasm;   Abdominal Neoplasm
Intervention: Dietary Supplement: Nutritional supplements
3 Completed
Has Results
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Conditions: Abdominal Neoplasm;   Colonic Neoplasm;   Mesothelioma;   Peritoneal Neoplasm
Interventions: Procedure: Surgery;   Procedure: Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin;   Drug: Postoperative dwell with paclitaxel and 5-FU
4 Completed Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
Condition: Abdominal Neoplasms
Interventions: Drug: enoxaparin;   Other: Physical prophylaxis
5 Recruiting EUS GUIDED Transduodenal Biopsy Using the 19G Flex
Condition: Abdominal Neoplasms
Intervention: Device: Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
6 Completed Restricted Intravenous Fluid Regime Effects on Immunological Indicators of Elderly Patients Operated for Abdominal Cancer
Conditions: Surgery;   Perioperative Care;   Immunization;   Abdominal Neoplasms
Interventions: Behavioral: perioperative fluid management;   Behavioral: perioperative fluid treatment
7 Unknown  Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients
Conditions: Abdominal Tumor;   Intestinal Obstruction;   Cirrhosis;   Intestinal Fistula;   Aneurism
Interventions: Drug: dexmedetomidine;   Drug: propofol
8 Recruiting Evaluation of Continuous Positive Airway Pressure for Tumor Motion Management in Radiotherapy
Conditions: Tumor Motion;   "Continuous Positive Airway Pressure";   Lung Cancer;   Breast Cancer;   Abdominal Tumors
Intervention: Device: Continuous positive airway pressure (CPAP)
9 Recruiting TAP Versus Thoracic Epidural in Major Abdominal Resections
Conditions: Malignant Neoplasm of Abdomen;   Surgery
Interventions: Drug: Exparel 1.33% (20ml Volume);   Drug: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
10 Active, not recruiting Avastin and Erlotinib as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer, and Papillary Serous Mullerian Tumors
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Papillary Serous Mullerian Cancer
Interventions: Drug: Avastin;   Drug: erlotinib;   Drug: paclitaxel;   Drug: carboplatin
11 Recruiting An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
Condition: Peritoneal Neoplasms
Intervention:
12 Unknown  Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: docetaxel;   Drug: idronoxil;   Other: placebo
13 Active, not recruiting Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Ovarian Carcinosarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Sarcoma;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Sarcoma;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ifosfamide;   Other: Quality-of-Life Assessment
14 Completed AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Renal Cell Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AFP464;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Recruiting HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry
Conditions: Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
Intervention:
16 Not yet recruiting Adjuvant HIPEC in High Risk Colon Cancer
Conditions: Colorectal Neoplasms;   Peritoneal Neoplasms
Interventions: Procedure: Adjuvant HIPEC (open/laparoscopic);   Drug: Standard adjuvant systemic chemotherapy;   Procedure: Diagnostic laparoscopy
17 Completed OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206
Conditions: Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Intervention: Drug: Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)
18 Completed
Has Results
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: tanespimycin
19 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Cisplatin;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
20 Completed
Has Results
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Conditions: Peritoneal Neoplasms;   Intestinal Obstruction;   Carcinomatosis
Interventions: Drug: Octreotide LAR;   Drug: Octreotide (Immediate release);   Drug: methylprednisolone;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years